US medtech stocks fall as Trump administration opens import probe

Reuters
09/25
US medtech stocks fall as Trump administration opens import probe

Sept 25 (Reuters) - U.S. medtech stocks fell on Thursday after the U.S. Commerce Department opened a probe into imports of medical devices, a move that could ultimately lead to tariffs.

Companies like GE HealthCare GEHC.O, Becton Dickinson BDX.N, Stryker SYK.N, Insulet PODD.O, Intuitive Surgical ISRG.O and ResMed RMD.N were among the worst performers on the S&P Health Care Equipment index .SPLRCMED, down between 3% and 9%.

Abbott ABT.N slipped 1.6% and Medtronic MDT.N fell 1.7%, with the S&P Health Care Equipment index dropping 1.6% on Thursday.

Medtech shares have been volatile this year, pressured by supply chain disruptions, cost inflation and slower demand in some international markets.

Analysts said the probe could have implications for a range of medical technology companies with globally sourced supply chains and could create a modest overhang for the stocks.

Earlier this month, the Secretary of Commerce launched a Section 232 investigation under the Trade Expansion Act of 1962 to assess how imports of personal protective equipment, medical consumables, and medical devices impact national security.

Section 232 allows the President to restrict imports if they are found to "threaten to impair" U.S. national security.

While the list of MedTech products covered is broad, we do not think it is right to hit the panic button in response to the announcement, J.P. Morgan analyst Robbie Marcus said in a note.

The department said it would make recommendations within 270 days.

"The U.S. is home to the world's leading and most innovative medical device industry, and we share the Administration's interest in further strengthening healthcare resilience and manufacturing locally," a GE HealthCare spokesperson said.

Shares in healthcare and industrial sectors across Europe also dipped.

(Reporting by Puyaan Singh, Sneha S K, Mrinalika Roy in Bengaluru; Editing by Tasim Zahid)

((mrinalika.roy@thomsonreuters.com;))

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10